NanoRepro AG (NN6.DE)
NanoRepro AG operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Marburg, HE, DE. The stock last traded at $1.98, down 5.26% on the session, giving a market capitalisation of $25.0M. Its beta of 0.52 implies it has historically moved less than the broad market.
Based in Marburg, Germany, NanoRepro AG specializes in the development, manufacturing, and international distribution of both swift diagnostic tests and nutritional supplements, serving individual consumers and healthcare professionals alike. Their diagnostic offerings encompass family planning, various disease detection, identification of food intolerances, allergies, and infectious diseases. This portfolio includes dedicated rapid test lines for allergies, family planning, and preventive healthcare. For hospitals and medical practices, they provide point-of-care tests capable of detecting conditions such as HIV, human cardiac Troponin I, D-dimer, streptococci antigens, influenza types A and B, and microalbumin. The company also produces immunochromatographic lateral flow tests for biomarker identification, alongside rapid SARS-CoV-2 antibody and antigen tests. Complementing their diagnostics, NanoRepro AG offers food supplements tailored for men and women, distributed via online stores and pharmacies.
NanoRepro AG is most often compared with the following Healthcare names: